Shots:

• AstraZeneca and IDT Biologika are exploring options to accelerate output of finished AZ’s COVID-19 vaccine in Q2’21 to support EU’s immediate vaccination needs during the pandemic
• The companies plan to strengthen EU’s vaccine manufacturing capability as they plan to invest in capacity expansion at IDT Biologika’s production site iGermany to build up to five 2-000-litre bioreactors capable of making 10M of doses/mos. The new assets anticipated to be operational by the end of 2022
• Following the EMA’s approval- millions of AstraZeneca vaccines began shipping on Feb 05- 2021 as part of the initial 17M doses that are due to be delivered over the next weeks- with more planned in Mar’2021

 ­ Ref: AstraZeneca | Image: Business Standard